» Articles » PMID: 15635516

Maximum Recommended Doses of Local Anesthetics: a Multifactorial Concept

Overview
Date 2005 Jan 7
PMID 15635516
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

The current recommendations regarding maximum doses of local anesthetics presented in textbooks, or by the responsible pharmaceutical companies, are not evidence based (ie, determined by randomized and controlled studies). Rather, decisions on recommending certain maximum local anesthetic doses have been made in part by extrapolations from animal experiments, clinical experiences from the use of various doses and measurement of blood concentrations, case reports of local anesthetic toxicity, and pharmacokinetic results. The common occurrence of central nervous system toxicity symptoms when large lidocaine doses were used in infiltration anesthesia led to the recommendation of just 200 mg as the maximum dose, which has remained unchanged for more than 50 years. In most cases, there is no scientific justification for presenting exact milligram doses or mg/kg doses as maximum dose recommendations. Instead, only clinically adequate and safe doses (ranges) that are block specific are justified, taking into consideration the site of local anesthetic injection and patient-related factors such as age, organ dysfunctions, and pregnancy, which may influence the effect and the pharmacokinetics of the local anesthetic. Epinephrine in concentrations of 2.5 to 5 microg/mL should be added to the local anesthetic solution when large doses are administered, providing there are no contraindications for the use of epinephrine. As a rule, conditions (eg, end-stage pregnancy, high age in epidural, or spinal block) or diseases (uremia) that may increase the rate of the initial uptake of the local anesthetic are indications to reduce the dose in comparison to one normally used for young, healthy, and nonpregnant adults. On the other hand, the reduced clearance of local anesthetics associated with renal, hepatic, and cardiac diseases is the most important reason to reduce the dose for repeated or continuous administration. The magnitude of the reduction should be related to the expected influence of the pharmacodynamic or pharmacokinetic change.

Citing Articles

Advanced Hydrogel Systems for Local Anesthetic Delivery: Toward Prolonged and Targeted Pain Relief.

Jeong J, Kim M, Kim S, Lee K, Choi H Gels. 2025; 11(2).

PMID: 39996674 PMC: 11854925. DOI: 10.3390/gels11020131.


The Study of Ropivacaine Pharmacokinetics in a Clinical Setting: A Critical Scoping Review from the Perspective of Analytical Methodologies.

Butiulca M, Farczadi L, Vari C, Imre S, Azamfirei L, Lazar A Int J Mol Sci. 2025; 25(24).

PMID: 39769250 PMC: 11678900. DOI: 10.3390/ijms252413487.


Bilateral Rectus Sheath Block with Continuous Bupivacaine Infusions After Elective Open Gastrectomy: A Randomized Controlled Trial.

Opincans J, Ivanovs I, Miscuks A, Pavulans J, Martinsone K, Rudzats A Medicina (Kaunas). 2025; 60(12.

PMID: 39768872 PMC: 11727647. DOI: 10.3390/medicina60121992.


Incidence of local anesthetic systemic toxicity in patients receiving bupivacaine infiltration analgesia for total joint arthroplasty under general anesthesia: a retrospective single-center study.

Tsai Y, Lin Y, Hsieh P, Liou J, Chung Y, Shih B BMC Anesthesiol. 2024; 24(1):422.

PMID: 39573988 PMC: 11580633. DOI: 10.1186/s12871-024-02816-y.


Optimization and comparison of unidirectional lidocaine-loaded buccal patch with the articaine-loaded buccal patch to reduce injection pain and increment of patients' compliance in dental procedures: A double-blind randomized controlled trial.

Panahandeh E, Ghassami E, Etemadi Sh M, Varshosaz J Heliyon. 2024; 10(16):e35533.

PMID: 39211919 PMC: 11357764. DOI: 10.1016/j.heliyon.2024.e35533.